DBV Technologies S.A.
DBVT
Rank in Stocks
#10460
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on... DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
Share Price
$11.05
Last synced: 2026-11-09
Market Cap
$691.14M
Change (1 day)
5.74%
Change (1 year)
-17.17%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade DBV Technologies S.A. (DBVT)
Category
Healthcare
EPS for DBV Technologies S.A. (DBVT)
EPS as of September 2026 TTM: $-2.35
According to DBV Technologies S.A.'s latest financial reports, its current EPS (TTM) is $-2.35. At the end of 2025 the company had an EPS of $-1.70, a decrease compared to its 2024 EPS of $-1.20.
EPS history for DBV Technologies S.A. from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.35 | 38.24% |
| 2025 | $-1.70 | 41.67% |
| 2024 | $-1.20 | 60.00% |
| 2023 | $-0.75 | -40.00% |
| 2022 | $-1.25 | -30.56% |
| 2021 | $-1.80 | -38.98% |
| 2020 | $-2.95 | 1.72% |
| 2019 | $-2.90 | -4.92% |
| 2018 | $-3.05 | -48.74% |
| 2017 | $-5.95 | 26.60% |
| 2016 | $-4.70 | 123.81% |
| 2015 | $-2.10 | 20.00% |
| 2014 | $-1.75 | -10.26% |
| 2013 | $-1.95 | 50.00% |
| 2012 | $-1.30 | 85.71% |
| 2011 | $-0.70 | 48.94% |
| 2010 | $-0.47 | 27.03% |
| 2009 | $-0.37 | -17.78% |
| 2008 | $-0.45 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -766.38% |
US
|
|
| $-7.07 | 200.85% |
US
|
|
| $-5.29 | 125.11% |
AU
|
|
| $12.88 | -648.09% |
BE
|
|
| $21.56 | -1,017.45% |
NL
|
Questions about DBV Technologies S.A.'s earnings per share (EPS)
What is DBV Technologies S.A.'s earnings per share (EPS)?
DBV Technologies S.A.'s earnings per share (EPS) over the last twelve months is $-2.35, as of Sep 2026.
What was DBV Technologies S.A.'s earnings per share (EPS) in 2025?
In 2025, DBV Technologies S.A.'s earnings per share (EPS) was $-1.70, compared with $-1.20 in 2024.
How has DBV Technologies S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, DBV Technologies S.A.'s earnings per share (EPS) was highest in 2023 ($-0.75) and lowest in 2020 ($-2.95).
How does DBV Technologies S.A.'s earnings per share (EPS) compare with similar companies?
DBV Technologies S.A.'s earnings per share (EPS) ($-2.35) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.